Print

GlaxoSmithKline (GSK) Process Using Pall Rapid Microbiological Test Is First Approved By FDA 
10/19/2005 5:11:32 PM

Pall Corporation (NYSE:PLL) announced today that the U.S. Food and Drug Administration (FDA) granted GlaxoSmithKline (GSK) approval to use the Pallchek(TM) Luminometer as part of the quality control process for its prescription nasal spray product in its Parma, Italy facility. The Pall rapid test enables GSK to release product to market up to four days earlier than before.
//-->